# Intellia Therapeutics Inc. (NTLA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.86, market value $1.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Intellia Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 27.9×**. Each dollar of revenue is priced at 27.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -21.0%** (5-yr avg -20.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -711.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -609.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -61.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -47.5%**. Each dollar of assets produces -47.5% of profit.

## Growth
- **Revenue growth (1 yr): 16.9%** (3-yr 9.1%/yr, 5-yr 3.1%/yr). Revenue grew 16.9% over the last year, against 3.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 27.4%**. Earnings per share rose 27.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 5.08** (quick 5.08). Current assets cover the next year's liabilities 5.08 times.
- **Altman Z-score: 5.91**. A Z-score of 5.91 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Intellia Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -9.3%** (YTD 31.9%, 3-mo 4.8%). The shares are down 9.3% over twelve months including dividends.
- **From 52-week high: -35.8%** (49.2% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 2.33** (volatility 80%). Beta of 2.33 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NTLA · Page: https://foliofundamentals.com/stocks/ntla

Not investment advice.